After receiving approval from both the Senate and the House of Representatives, two pieces of bipartisan US legislation aimed improving education around biosimilars and lowering drug costs are now headed for US president Joe Biden’s consideration.
“Passing these bills in Congress has the potential to lower prescription costs for patients, but also for taxpayers, because taxpayers...




